Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC
Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC
This is a single arm, open-label, non-randomized and single-center phase I/II clinical study,
 to evaluate the the safety, tolerance and efficacy of Lenvatinib plus Camrelizumab as
 first-line therapy in patients with advanced Hepatocellular Carcinoma.
The purpose of this study is to evaluate the safety, tolerance and efficacy of Lenvatinib
 combined with Camrelizumab as first-line therapy for patients with advanced hepatocellular
 carcinoma.The target sample size is 53.In the first phase 6 panticipants was evaluated
 (N=3+3), If there was no obvious dose-limiting toxicity (DLT), then entered the extended
 phase (N=47).Treatment continually until disease progression or intolerable toxicity or
 patients withdrawal of consent.
Inclusion Criteria:

 1. Voluntary agreement to provide written informed consent and the willingness and
 ability to comply with all aspects of the protocol;

 2. Males or females, age ≥ 18 years at the time of informed consent;

 3. Imaging (by AASLD or Standard for the diagnosis and treatment of primary liver cancer
 2017 in China) or histopathologically or cytologically confirmed advanced HCC;

 4. BCLC stage B or C, and not suitable for surgical or local therapy, or has progressed
 following surgical and/or local therapy;

 5. No previous systematic treatment for HCC;

 6. Have at least one measurable lesion (in accordance with RECIST v1.1); the measurable
 lesion has a long diameter ≥ 10 mm or lymphadenopathy has a short diameter ≥ 15 mm in
 spiral CT scan;

 7. ECOG-PS score 0 or 1

 8. Child-Pugh Class: Grade A

 9. Life Expectancy of at least 3 months

 10. Subjects with HBV infection: HBV DNA<2000 IU/ml or <10^4 copy/mL, and have received
 anti-HBV therapy for at least 14 days prior to enrollment in the study, subjects with
 HCV-RNA(+) must receive antiviral therapy;

 11. Hematology and organ functions are sufficient based on the following laboratory
 results within 14 days prior to the treatment of this study:

 Whole blood cell examination (no blood transfusion within 14 days, no G-CSF use and no
 drugs use): WBC ≥ 3.0×10^9/L, HB ≥ 85 g/L; Neutrophils ≥ 1.5×10^9/L; PLT≥75×10^9/L;
 Biochemical examination (no ALB infused within 14 days): ALB ≥ 29 g/L; ALP and ALT and
 AST < 5×ULN; TBIL≤3×ULN; Adequate renal function: Cr≤1.5×ULN, or CCr>50mL/min; Female:
 CrCl = ((140- year) x weight (kg) x 0.85)/72x Cr (mg/dL) Male: CrCl = ((140- year) x
 weight (kg) x 1.00)/72xCr (mg/dL)

 12. Agree to abstain from sex (avoid heterosexual intercourse) or use contraceptive
 methods with an annual contraceptive failure rate of less than 1% during treatment and
 for at least 6 months after the last administration.

 Exclusion Criteria:

 1. Hepatocellular carcinoma patients with any of the following:

 Suitable for radical surgery; without an assessment lesion after radical surgery;
 liver transplantation history or ready for liver transplantation;

 2. History of hepatic encephalopathy;

 3. Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar
 cell carcinoma;

 4. Pregnant women (positive pregnancy test before taking medicine) or lactating women;

 5. Known history of serious allergy to any monoclonal antibody or targeted
 anti-angiogenic drug (or any excipient);

 6. Received any topical treatment within 4 weeks prior to the study, including but not
 limited to surgery, radiotherapy, hepatic artery embolization, TACE, hepatic artery
 perfusion, radiofrequency ablation, cryoablation or percutaneous ethanol injection;

 7. Previous or existing CTCAE 5.0 standard grade 3 or above gastrointestinal fistula or
 non-gastrointestinal fistula (such as skin);

 8. Factors to affect oral administration and absorption (such as inability to swallow,
 chronic diarrhea and intestinal obstruction);

 9. Ascites with clinical symptoms (i.e. ascites with Child-Pugh rating > 2) or cancerous
 ascites require therapeutic abdominal puncture or drainage. Or uncontrolled malignant
 ascites (ascites that researchers believe diuretics or puncture cannot control);

 10. Major surgical operations (except biopsy) were performed within 4 weeks prior to the
 first study of drug therapy or the surgical incision was not completely healed; Minor
 surgery (i.e. simple resection, biopsy, etc.) was performed within 7 days before the
 first round of research intervention.

 11. Cardiovascular and cerebrovascular diseases with significant clinical significance,
 including but not limited to acute myocardial infarction, severe/unstable angina
 pectoris, cerebrovascular accident or transient ischemic attack, congestive heart
 failure occurred within 6 months prior to admission (New York Heart Association Grade
 ≥2, see Appendix 4); Arrhythmia requiring antiarrhythmic drugs (except β receptor
 blocker or digoxin); Repeated ECG detection QTcF interval>480 milliseconds (ms).

 12. Hepatic and renal insufficiency, such as jaundice, ascites, and/or bilirubin>3×ULN,
 creatinine ratio>3.5g/24h, or renal failure requiring blood or peritoneal dialysis,
 etc. And/or urine routine showed proteinuria ≥++or confirmed 24-hour proteinuria>1.0g.

 13. Persistent>2 grade (CTC-AE5.0) infection.

 14. History of thromboembolism (including stroke and/or transient ischemic attack) in the
 past 6 months.

 15. Hypertension (systolic blood pressure>160mmHg, diastolic blood pressure>100 mmHg) that
 not be well controlled through antihypertensive drug treatment.

 16. History of active autoimmune diseases or autoimmune diseases in the past two years.

 17. Known central nervous system metastasis and/or cancerous meningitis.

 18. Be ready for or previously received organ or allogenic bone marrow transplantation.

 19. Known history of active tuberculosis (Mycobacterium tuberculosis).

 20. History of gastrointestinal hemorrhage within 6 months prior to the start of study
 treatment or clear tendency of gastrointestinal hemorrhage.

 21. History of human immunodeficiency virus (HIV)infection.

 22. Active hepatitis B virus or C virus infection and not receive regular treatment;

 23. Serious non-healing wound, ulcer or fracture.

 24. Drug abuse exists; or any medical, psychological or social condition that may affect
 research, unstable patient compliance or even endanger patient safety.

 25. Any>1 grade (CTC-AE 5.0) unresolved toxicity due to previous treatment or operation,
 except for hair loss, anemia, and hypothyroidism.

 26. Previous and current evidence of pulmonary fibrosis, interstitial pneumonia,
 pneumoconiosis, radiation pneumonitis, drug-associated pneumonia and severe impairment
 of lung function.

 27. Received a potent CYP3A4 inhibitor treatment within 7 days prior to the study or
 received a potent CYP3A4 inducer within 12 days prior to the study.

 28. With other active malignant tumors except HCC within 5 years or simultaneously.

 29. Patients are unsuitable for participation in this research after comprehensive
 assessment by the researchers.

 30. Patients participate in another clinical study at the same time.